Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Glioblastoma 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Renal Insufficiency 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Lung Neoplasms 1Liver Failure 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Astrocytoma 1Ann Arbor Stage III Non-Hodgkin Lymphoma 1Advanced Malignant Solid Neoplasm 1

Interventions

Magnetic Resonance Spectroscopy 14Temozolomide 10Specimen Handling 10X-Rays 8Radiotherapy 7Biopsy 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6trametinib 5dabrafenib 4ulixertinib 3olaparib 3larotrectinib 3erdafitinib 3Radiotherapy, Intensity-Modulated 3Nivolumab 3tipifarnib 2selpercatinib 2pembrolizumab 2palbociclib 2niraparib 2ivosidenib 2ensartinib 2atezolizumab 2abemaciclib 2Surveys and Questionnaires 2Radiation 2Proton Therapy 2Lomustine 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Glioma × veliparib × Clear all
NCT03581292 2026-05-27

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

National Cancer Institute (NCI)

Phase 2 Active not recruiting
38 enrolled 13 charts
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡